AiCure announced the initiation of a major clinical trial assessing the company’s advanced facial recognition and motion-sensing technology to monitor and intervene with patients on maintenance therapy for opioid addiction.

The novel platform utilizes HIPAA-compliant facial recognition and motion sensing software on mobile devices to automate directly observed therapy by visually and automatically confirming that the correct patient is taking the prescribed dose at the appropriate time. No human review is needed to confirm the process of medication administration and patients who do take incorrect doses or do not use the software are automatically flagged for immediate follow-up.

RELATED: Drug Poisoning Deaths Quadruple, While Other Causes of Injury Deaths Down

AiCure has received $1 million from the National Institute on Drug Abuse (NIDA) to assess the efficacy of this platform on increasing patient adherence to buprenorphine/naloxone (Suboxone; Reckitt Benckiser) maintenance therapy compared to treatment-as-usual (TAU). Secondary outcomes include reduced use of illicit opioids, increased length of stay in treatment, and fewer drug-related problems. The usability/feasibility of the technology and its acceptance by patients will also be evaluated. Preliminary results of the trial (currently being conducted at the University of Cincinnati) are expected to be published in August 2015.

For more information visit